Abstract: The term bispecific antibody (bsAb) is used to describe antibodies that can recognize and bind two different antigens. Compared with the regular therapeutic antibodies, bsAbs have many advantages, such as higher sensitivity, better specificity, and are able to block multiple disease pathways simultaneously. So far, 3 bispecific antibodies have been marketed and nearly 100 are in clinical development all over the world, showing a broad development prospect. Immunogenicity of bispecific antibodies refers to the fact that the drugs will cause the immune response and produce anti-drug antibodies after entering the body, which may affect the pharmacokinetic and pharmacodynamic properties of the drugs. In this paper, the research progress on the immunogenicity of catumaxomab, blinatumomab and emicizumab was reviewed, with a view to providing reference for the safety, efficacy, and rational clinical application of bispecific antibodies.

Key words: bispecific antibodies, catumaxomab, blinatumomab, emicizumab, immunogenicity